T-67 days before @ascocancer.bsky.social #ASCO26! I am looking forward to the largest oncology event of the year and specifically to the multiple #globaloncology sessions 🌐scheduled throughout the meeting.
See you all in #Chicago where you get to experience all these 🌞🍃🌧️ within a day! 😄
Great to hear Dr @herbloongmd.bsky.social speak about immunotherapy clinical trials at Apollo Proton Cancer Centre in Chennai, India.
It was great finally meeting you in person @dtsang.ca! Heard so much about you from everyone around! 😀
Putting some last minute slides together 😂.
Flight delayed from #HKG to #FRA so not sure whether we can make the transit, but #GütenMorgenAlles and see you in person at Berlin for @myESMO #ESMO25!
#sarcoma #LCSM @ctosociety @apoddc @APCLC_2023
Looking forward to playing with @drsanjaypopat.bsky.social - a lot of fun rehearsing covers and @mayhemtomi tracks. Check us out tonight @iaslc.bsky.social #wclc2025
The @ascocancer.bsky.social
#InternationalAffairsCommittee #2025-26. An absolute delight and pleasure working with these highly engaged professionals from across the world 🌎 and across oncology disciplines. #BestASCOCommittee
It's always a pleasure meeting #colleagues on home turf in #hongkong 🇭🇰 after a long day of clinic. #LCSM @cuhkmedicine.bsky.social
Whirlwind 2 days in #Manila at #PSMO
@astra-zeneca.bsky.social 🫁 #lungcancer #preceptorship w/ colleagues & experts including @KSamalaMD #ArthurLui 🇵🇭 together w/ #QuincyChu of @AlbertaUni 🇨🇦. Covered broad topics: #targetedtherapies, #IO, #EGFR and #SCLC. #LCSM
@cuhkmedicine.bsky.social @APCLC_2023
Enhancing cost-effectiveness considerations in the adoption of new drugs in Hong Kong www.hkmj.org/abstracts/v3...
#ImprovingAccess to #effectivetherapies is mandate all physicians should uphold. How to incorporate these whilst balancing societal costs require guidelines & discussions. Our position paper on "Enhancing cost-effectiveness considerations in adoption of new drugs in HK" www.hkmj.org/earlyrelease...
The Strong International Camaraderie Between Past and Present Fellows of the PMH Fellowship - Herbert Loong
@herbloongmd.bsky.social
@pmresearch-uhn.bsky.social
oncodaily.com/blog/herbert...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #PMHFellowship
🇭🇰🚝✈️🇨🇦🚗🏥=🤩 Looking forward to #returning to #Toronto & my alma mater @uhnresearch.ca #PrincessMargaretCancerCentre for a short visit this weekend! Very honoured and privileged to be able to give #GrandRounds 🎙️
Best way to fight jetlag! See you soon!👋
#LCSM #Sarcoma #CUHKSarcoma #precisiononcology
Putting final touches together to my talk😀. Looking forward to welcoming you all to #hongkong 🇭🇰 for #ESMOTATAsia25! Don't be shy - come by and say hi!
#drugdevelopment @cuhkmedicine.bsky.social @apoddc @APCLC_2023
#PublicEducation on #sarcomas can be fun! 😃 #facialkexpressions #CannotHideHit #HappyMonday #CUHKSarcoma
youtu.be/XesQlcQPMOY?...
One week until the inaugural #ESMOTATAsia25 🤩
I'm looking forward to joining global drug development experts in🍜🇭🇰
+ sharing insights on dose optimisation of novel combinations
🗓️ Saturday 19 July 2pm.
@myesmo.bsky.social @herbloongmd.bsky.social @anmwongnz.bsky.social
Incorporating high-risk individuals beyond smoking history into lung cancer screening in Hong Kong: a cost-effectiveness study - JTO Clinical and Research Reports www.jtocrr.org/article/S266...
Thanks @liferaftgroup.bsky.social for opportunity to share some key #GIST updates from #ASCO25 w/ wider patients' community 🌎 through this webinar last week.
@srothschild @cuhkmedicine.bsky.social @GISTNetwork @ctosociety #DrugDevelopment #sarcomas #CUHKSarcoma
youtu.be/uoZULT8YlPU?...
Come join us in a couple of hours as we discuss several #abstracts related to #GISTs presented at #ASCO25!
Registration is free! Register here: us02web.zoom.us/webinar/regi...
@liferaftgroup.bsky.social @ctosociety #sarcoma @cuhkmedicine.bsky.social #CUHKSarcoma #PublicEducation
After serving on #MembershipCommittee, I look forward to returning to #CommunicationsCommittee
@iaslc.bsky.social w/ #LCSM colleagues from around the World 🌐 to create #effective, #efficient & #robust channels of communications between our society & community. @CUHKMedicine @apoddc @APCLC_2023
Sevabertinib Induces Durable Response in Advanced HER2-Mutant NSCLC #lungcancer #NSCLC #ASCO25 @herbloongmd.bsky.social @ascocancer.bsky.social
www.onclive.com/view/sevaber...
#Honoured and #humbled to have been awarded #FASCO at @ascocancer.bsky.social #ASCO25. My thanks to my friends and colleagues for your overwhelming support along the way 😊
#sarcoma #LCSM #InternationalAffairsCommittee #drugdevelopment #precisiononcology
Thanks @stern-sydney.bsky.social! I am humbled and credits should go to you for all that you are doing for the #TGCT community and beyond! Looking forward to seeing your presentation! 😀 #CTOSTweeTOS #Sarcoma
T-13hrs 59mins before landing in #Chicago for @ascocancer.bsky.social #ASCO25! ✈️ full of oncology colleagues from 🇭🇰🇵🇭 and from 🇦🇺🦘🐨😀.
What’s the combined H-index of this flight? 🧐
Looking fwd to days of #scientificexchanges and #interactivediscussions. Safe travels everyone! See you at McCormick!
As @ascocancer.bsky.social #ASCO25 is round the corner, so is the end of my #chair of #InternationalAffairsCommittee.
Tks all my colleagues & friends from around the World 🌍 for continuous support.
Time to pass torch 🔥 to Dr. Monica Malik who will continue to push our global agenda forward!
Come join us in #hongkong 🇭🇰 🍜🥟🥡 for the #inaugural @myesmo.bsky.social #ESMOTATAsia25 on July 18-20, 2025! We have assembled a #stellar group of #international #faculties and #experts in #drugdevelopment to help move the field forward. Register today!
Thanks to Dr Herbert Loong, of The Chinese University of Hong Kong, for speaking with us during #AACR25 about the efficacy of D3S-001 in KRAS G12C inhibitor–resistant NSCLC! See our site for more meeting insights! @theaacr.bsky.social #lcsm #oncology
www.onclive.com/conference/a...
Thanks my #coinvestigators for opportunity to present data of #D3S_001, a novel #KRASG12C inhibitor in #G12Ci pre-treated #NSCLC at @theaacr.bsky.social #AACR25. Strong & rapid #targetengagement confer superior #efficacy c.f. 1st generation G12Ci.
✔️ORR 30%; DCR 80% in KRASG12Ci pre-treated popn.
Better late than never! 🤣 Arrived in #Chicago for @theaacr.bsky.social #AACR25 after 14 hours flight ✈️ and looking forward to the #ClinicalTrials #Minisymposium tomorrow.
Wonderful opportunity to #share & #discuss emerging role of #TCellEngagers #BiTEs in Mx of #SCLC 🫁 w/ our Malaysian 🇲🇾 colleagues during #LCS2025.
Small group discussions (esp. over a meal! 😋) are always very interactive for experience sharing.
#LCSM @APCLC_2023 @apoddc @cuhkmedicine.bsky.social
📢The @ctosociety #SpringWebinar is taking place in < 72hours! Come join our #international faculty on #EwingSarcoma as we take deep dive into similarities and differences of this "same" disease in #paediatrics and #adults patients!
Register today at: ctos.org/EducationalP...
#CTOSTweeTOS #sarcoma
